Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

946 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group. Colao A, et al. Among authors: sheppard m. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423324 Free PMC article. Clinical Trial.
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6. Pituitary. 2015. PMID: 25103549 Free PMC article. Clinical Trial.
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P; Pasireotide C2305 Study Group. Bronstein MD, et al. Among authors: sheppard m. BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8. BMC Endocr Disord. 2016. PMID: 27039081 Free PMC article. Clinical Trial.
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Pituitary. 2015 Jun;18(3):395-6. doi: 10.1007/s11102-014-0628-z. Pituitary. 2015. PMID: 25566750 Free PMC article. No abstract available.
Management of acromegaly in Latin America: expert panel recommendations.
Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M. Barkan A, et al. Among authors: sheppard m. Pituitary. 2010 Jun;13(2):168-75. doi: 10.1007/s11102-009-0206-y. Pituitary. 2010. PMID: 19882249 Free PMC article. Review.
Medical therapy in acromegaly.
Sherlock M, Woods C, Sheppard MC. Sherlock M, et al. Among authors: sheppard mc. Nat Rev Endocrinol. 2011 May;7(5):291-300. doi: 10.1038/nrendo.2011.42. Epub 2011 Mar 29. Nat Rev Endocrinol. 2011. PMID: 21448141 Review.
Primary medical therapy for acromegaly.
Sheppard MC. Sheppard MC. Clin Endocrinol (Oxf). 2003 Apr;58(4):387-99. doi: 10.1046/j.1365-2265.2003.01734.x. Clin Endocrinol (Oxf). 2003. PMID: 12641619 Review.
946 results